Astellas Pharma Forecast, price target & analysts
Why the stock moved Beta
Astellas Pharma Target price 2026 - Analyst rating & recommendation
Astellas Pharma Classifications & Recommendation:
Astellas Pharma Price Target
| Target Price | ¥1,861.50 |
| Price | ¥2,185.50 |
| Deviation |
14.83%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Astellas Pharma 2027 .
The average Astellas Pharma target price is ¥1,861.50.
This is
14.83%
register free of charge
¥2,520.00
15.31%
register free of charge
¥1,313.00
39.92%
register free of charge
|
|
| A rating was issued by 20 analysts: 9 Analysts recommend Astellas Pharma to buy, 10 to hold and 1 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Astellas Pharma stock has an average upside potential 2027 of
14.83%
register free of charge
|
Sales and Margin forecast 2026, 2027 & 2028
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion ¥ | 1,912.32 | 2,028.61 |
| 19.25% | 6.08% | |
| EBITDA Margin | 20.93% | 23.67% |
| 50.25% | 13.08% | |
| Net Margin | 2.65% | 9.81% |
| 149.67% | 269.67% |
16 Analysts have issued a sales forecast Astellas Pharma 2026 . The average Astellas Pharma sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an Astellas Pharma EBITDA forecast 2026. The average Astellas Pharma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
15 Astellas Pharma Analysts have issued a net profit forecast 2026. The average Astellas Pharma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Mar '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share ¥ | 28.24 | 111.15 |
| 198.20% | 293.59% | |
| P/E | 19.13 | |
| EV/Sales | 2.11 |
15 Analysts have issued a Astellas Pharma forecast for earnings per share. The average Astellas Pharma EPS is
This results in the following potential growth metrics and future valuations:
Astellas Pharma...
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
